Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL896518 | 0.83 | KMT2A (0.38) | TRPV1NPC1NPSR1 | |
| SCHEMBL896651 | 0.83 | TRPV1 (0.45) | TRPV1NPC1NPSR1 | |
| SCHEMBL896380 | 0.83 | NPC1 (0.37) | TRPV1NPC1NPSR1 | |
| SCHEMBL896684 | 0.80 | MAPT (0.38) | HTTNPC1NPSR1 | |
| SCHEMBL896816 | 0.79 | DRD1 (0.45) | TRPV1SCN5ASCN9A | |
| SCHEMBL27637538 | 0.78 | TRPV1 (0.52) | TRPV1SCN5ASCN9AHSD11B1 | |
| SCHEMBL896348 | 0.77 | KMT2A (0.40) | TRPV1NPC1NPSR1 | |
| SCHEMBL896634 | 0.76 | NPC1 (0.40) | TRPV1NPC1NPSR1 | |
| SCHEMBL896765 | 0.74 | L3MBTL1 (0.48) | HTTHSD11B1NPC1NPSR1 | |
| SCHEMBL896631 | 0.71 | PTGS2 (0.36) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598176-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258136-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-04 | — | — | US | disclosed |
| CN-101326176-B | Pyridazine compound and use thereof | SUMITOMO CHEMICAL CO | 2012-05-30 | — | — | CN | disclosed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
| EP-1958946-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-1958946-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-05 | — | — | US | disclosed |
| CN-101326176-A | Pyridazine compound and use thereof | SUMITOMO CHEMICAL CO (JP) | 2008-12-17 | — | — | CN | disclosed |
| EP-1958946-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1958946-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | TRPV1 2363/4885HTT 2390/4885SCN5A 310/4885 |
| US-20090275589-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, PDXK | TRPV1 2363/4885HTT 2390/4885SCN5A 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.